PURPOSE To describe the characteristics of new users of cilostazol in Europe with the aim to support the evaluation of its benefit/risk as used in regular clinical practice before the implementation of labeling changes recommended by the European Medicines Agency. METHODS New users of cilostazol were identified in populations enrolled in five European health automated databases in the UK (The...

BACKGROUND Antiplatelet drugs are effective in preventing recurrence of atherosclerosis in type 2 diabetic patients. However, the efficacy and usefulness of 2 different antiplatelet drugs, aspirin and cilostazol, in the progression of carotid intima-media thickening are unknown. METHODS AND RESULTS To compare prevention by cilostazol and aspirin of progression of atherosclerosis, we conducted...

Inhibitors of cyclic nucleotide phosphodiesterase hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate are known to inhibit platelet aggregation, which plays an important role in acute reocclusion after thrombolysis in acute myocardial infarction. In the present study of a canine preparation of coronary artery thrombosis superimposed on high-grade stenosis, we ...

Background—Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator. This prospective, randomized, placebo-controlled, parallel-group clinical trial evaluated the efficacy of cilostazol for treatment of stable, moderately severe intermittent claudication. Methods and Results—Study inclusion criteria included age $40 year...

Background: Cilostazol was launched in Germany in 2007 for the treatment of patients with peripheral arterial occlusive disease (PAOD) stage II (intermittent claudication). It is indicated for second-line use when lifestyle modification or other interventions do not result in a decrease of PAOD symptoms. Materials and methods: The objective of this non-interventional study was to gain insight r...

A prospective, multicenter, cohort study from Italy December 2016 to 2018. For 287 patients with chronic limb-threatening ischemia (CLTI) who underwent open, endovascular, or hybrid lower extremity revascularization, the 30-day major adverse cardiovascular and limb events (MALE) rates were 3% 2%, respectively. At 1 year, overall survival, amputation-free freedom MALE, primary patency rate was 8...

Abstract Reactive oxygen species and oxidative stress impair β-cell function and reduce insulin secretion. It has been shown that progesterone and cilostazol possess antioxidant properties. The present study was aimed to investigate in vitro pretreatment effect of progesterone and cilostazol on insulin secretion as well as their protective effects against hydrogen peroxide-induced oxidative str...

BACKGROUND Shortening tuberculosis treatment could significantly improve patient adherence and decrease the development of drug resistance. Phosphodiesterase inhibitors (PDE-Is) have been shown to be beneficial in animal models of tuberculosis. We assessed the impact of PDE-Is on the duration of treatment in tuberculous mice. METHODS We analyzed the time to death in Mycobacterium tuberculosis...

BACKGROUND The mechanisms underlying the ability of cilostazol to improve walking distance in patients with intermittent claudication (IC) are not fully understood, but may be related to its phosphodiesterase type 3 (PDE3) and adenosine uptake inhibition. In the present study the effect of cilostazol on blood flow and interstitial adenosine concentration was compared with that of the PDE3 inhib...

Abstract Reactive oxygen species and oxidative stress impair β-cell function and reduce insulin secretion. It has been shown that progesterone and cilostazol possess antioxidant properties. The present study was aimed to investigate in vitro pretreatment effect of progesterone and cilostazol on insulin secretion as well as their protective effects against hydrogen peroxide-induced oxidative str...